EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Poor Agreement Among Asthma Specialists on the Choice and Timing of Initiation of a Biologic Treatment for Severe Asthma Patients

Andréanne Côté, Rosalie Beaulé, Marie-Ève Boulay, Jakie Guertin, Louis-Philippe Boulet, Krystelle Godbout, David Price

The Journal of Allergy and Clinical Immunology: In Practice · 2025

DOI: 10.1016/j.jaip.2025.01.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025. Verfasst von Andréanne Côté und 6 weiteren Autor:innen. Beteiligte Einrichtung: Quebec Heart and Lung Institute-Université Laval, Québec City, Quebec, Canada; Faculty of Medicine, Université Laval, Québec City, Quebec, Canada. El…. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents, Antibodies, Monoclonal, Practice Patterns, Physicians'. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Because the number of monoclonal antibodies available for severe asthma is growing, specialists currently choose without clear guidelines. Despite increasing knowledge on treatment response to these monoclonal antibodies, making the optimal choice for each individual patient remains a challenge. However, evidence of this daily challenge is lacking. OBJECTIVE: To evaluate interobserver agreement on the choice of biologic therapy in severe asthma patients among severe asthma specialists, based on clinical cases. METHODS: This 2-phase study included a pilot local study and an international validation study. Asthma specialists were presented 7 real-life asthma cases managed with a monoclonal antibody. Based on the clinical information provided in the cases, they were asked whether they would have initiated a monoclonal antibody and, if so, their treatment of choice between (1) omalizumab, (2) mepolizumab, (3) reslizumab, (4) benralizumab, and (5) dupilumab. Interobserver agreement for each question was assessed using Gwet agreement coefficient (AC1). RESULTS: Sixteen physicians from the Province of Quebec (Canada) completed the pilot survey, and 70 physicians from 26 countries completed the international survey. The Gwet AC1 for the decision to initiate a biological therapy was 0.48 in the pilot survey and 0.33 in the international survey. For the choice of therapy, agreement was 0.33 and 0.26, respectively. CONCLUSIONS: The interobserver agreement among asthma specialists in both the decision to initiate a biological treatment in patients with severe asthma and the selection of treatment is weak. These results highlight the need for studies seeking reliable predictors for optimal response to biological therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsAntibodies, MonoclonalPractice Patterns, Physicians'Biological TherapyHumansMaleFemalePilot ProjectsMiddle AgedAntibodies, Monoclonal, HumanizedAdultObserver VariationOmalizumabSeverity of Illness Index

Stichwörter der Autor:innen

Asthma specialistsBiologic therapyBiomarkersSevere asthma

Substanzen

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedmepolizumabbenralizumabAntibodies, MonoclonalreslizumabdupilumabOmalizumab

Autor:innen und Institutionen

  • Quebec Heart and Lung Institute-Université Laval, Québec City, Quebec, Canada; Faculty of Medicine, Université Laval, Québec City, Quebec, Canada. Electronic address: andreanne.cote@criucpq.ulaval.ca.
  • Quebec Heart and Lung Institute-Université Laval, Québec City, Quebec, Canada; Faculty of Medicine, Université Laval, Québec City, Quebec, Canada.
  • Quebec Heart and Lung Institute-Université Laval, Québec City, Quebec, Canada.
  • Faculty of Medicine, Université Laval, Québec City, Quebec, Canada.
  • Observational and Pragmatic Research Institute, Singapore, Singapore; Optimum Patient Care Global, Cambridge, UK; Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, U…

Zitieren

APA

Côté, A., Beaulé, R., Boulay, M. È., Guertin, J., Boulet, L. P., Godbout, K., & Price, D. (2025). Poor Agreement Among Asthma Specialists on the Choice and Timing of Initiation of a Biologic Treatment for Severe Asthma Patients. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2025.01.017

Vancouver

Côté A, Beaulé R, Boulay MÈ, Guertin J, Boulet LP, Godbout K, et al. Poor Agreement Among Asthma Specialists on the Choice and Timing of Initiation of a Biologic Treatment for Severe Asthma Patients. The Journal of Allergy and Clinical Immunology: In Practice. 2025. doi:10.1016/j.jaip.2025.01.017

BibTeX
@article{Ct2025,
  author = {Côté, Andréanne and Beaulé, Rosalie and Boulay, Marie-Ève and Guertin, Jakie and Boulet, Louis-Philippe and Godbout, Krystelle and Price, David},
  title = {Poor Agreement Among Asthma Specialists on the Choice and Timing of Initiation of a Biologic Treatment for Severe Asthma Patients},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2025},
  doi = {10.1016/j.jaip.2025.01.017}
}
Kostenlos starten →